by Paul McIntosh | Jul 7, 2021 | 2021, Press Releases
NovaBiotics were highlighted in Jonathan Smith’s article in Labiotech on “Scotland’s Top Ten Biotech Companies to Watch Out For.” Learn more about Scotland’s “thriving life sciences ecosystem” by accessing the article Labiotech Article Scotland’s Top Ten...
by Paul McIntosh | Jun 21, 2021 | 2021, Press Releases
Randomized embedded multi-factorial platform trial to provide accelerated, real-world evidence in community acquired pneumonias including COVID-19, influenzas and bacterial pneumonias Aberdeen, June 21, 2021. NovaBiotics Ltd, a privately held clinical stage company...
by Paul McIntosh | Jun 1, 2021 | 2021, Press Releases
Peer reviewed journal article highlights Company’s novel antifungal peptide’s activity against a broad range of fungal pathogens with no off target cytotoxicity Aberdeen, June 1, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune...
by Paul McIntosh | Mar 30, 2021 | 2021, Blog Post
By Grant Ellis, Director, NovaBiotics Ltd A number of commentators are now saying that as a result of the vaccines, COVID 19 will be akin to flu – something that comes around every year but for most of us nothing more than an inconvenience and only severely...
by Paul McIntosh | Feb 26, 2021 | 2021, Press Releases
Aberdeen, UK – 26th February 2021 – NovaBiotics Ltd, the clinical-stage anti-infectives biotechnology company, today announced that it has entered into a licensing agreement with an undisclosed partner to commercialise its NP213 peptide in a topical (brush/paint-on)...
by Paul McIntosh | Dec 31, 2020 | 2020, Blog Post
By Grant Ellis, Director NovaBiotics Ltd Back in October I quoted Sir Patrick Vallance, the government’s Chief Scientific Adviser saying that no vaccine for Covid was likely before the spring of 2021. We all now know that there are two vaccines that have been...
Contact Us
News and Events
Technology
Recent Comments